Sight Sciences, Inc. 8-K

What Happened
Sight Sciences, Inc. announced on April 23, 2026 that the U.S. District Court for the District of Delaware entered a Final Judgment on April 22, 2026 in the company's 2021 patent infringement suit against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. The Final Judgment upheld a jury finding that Sight Sciences’ asserted patent claims (U.S. Patents 8,287,482; 9,370,443; 11,389,328) are valid and were willfully infringed by Alcon in connection with sales of the Hydrus® Microstent. The court awarded Sight Sciences $55.4 million in monetary damages and an ongoing royalty of 10% of Hydrus revenue through the expiration of the last of the patents.

Key Details

• Total award: $55.4 million, composed of:
  • $34.0 million in past damages through the jury verdict date (April 26, 2024)
  • $14.7 million in supplemental damages through March 31, 2026
  • $6.8 million in pre- and post-judgment interest through April 17, 2026
• Ongoing remedy: 10% royalty on Hydrus revenue until the last asserted patent expires.
• Procedural status: Final Judgment is subject to appeal by Alcon; no monetary collection will occur unless appeals are exhausted or the appeal period lapses. Interest and royalties will continue to accrue during any appeal.
• Additional risk: Alcon has pursued ex parte reexamination proceedings; an adverse, final, non‑appealable decision in those proceedings could affect Sight Sciences’ ability to collect.

Why It Matters
If the Final Judgment is ultimately upheld after any appeals, Sight Sciences would have a confirmed $55.4M damages award plus a 10% royalty stream on Hydrus sales, which could be meaningful to revenue and cash flow. However, receipt of any money is contingent on the appeals process and potential outcomes of Alcon’s reexamination efforts, so investors should monitor legal developments, appeals timelines, and any announcements about collection or settlements.